IL-6 Genomic Variants and Risk of Prostate Cancer

To evaluate the role of Interleukin-6 (IL-6) single nucleotide polymorphisms in prostate cancer (PCa) and benign prostate hyperplasia (BPH)Material and Methods: We genotyped two IL-6 intronic variants (rs1800795 and rs2069845) in PCa cases, BPH cases and healthy men referred to Labbafinejad and Shohadaye Tajrish Medical Centers using tetra ARMS-PCR method.

The study included 130 PCa cases, 200 BPH cases and 200 healthy men. The C allele of rs1800795 was associated with PCa risk in the assessed population (OR (95% CI) = 1.45 (1.06-1.98)). However, the frequency of rs2069845 variants was not significantly different between PCa, BPH and control groups. The A C haplotype (rs2069845 and rs1800795 respectively) was associated with PCa and BPH risk (OR (95% CI) = 1.67 (1.12- 2.48); OR (95% CI)= 1.78 (1.25 - 2.54)). Besides, the A G haplotype (rs2069845 and rs1800795 respectively) has a protective effect against both PCa and BPH in the assessed population (OR (95% CI) = 0.63 (0.46-0.87); OR (95% CI)= 0.6 (0.45-0.79)).

Consequently, the results of the current study provide further evidence for contribution of IL-6 in prostate cancer.

Urology journal. 2018 Oct 21 [Epub ahead of print]

Mohammad Taheri, Rezvan Noroozi, Azadeh Rakhshan, Molud Ghanbari, Mir Davood Omrani, Soudeh Ghafouri-Fard

Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ., Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Department of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.